Key Points
- Five focused ultrasound companies recently released new funding announcements.
- See updates from HistoSonics, EDAP, Sonomind, SecondWave Systems, and Petal Surgical.
HistoSonics Announces Oversubscribed $250 Million Growth Financing
Since it was acquired for $2.25 billion in August 2025, HistoSonics has raised another $250 million to fund the commercial and clinical expansion of its cancer treatment technology. Supporters in the latest funding round include Bezos Expeditions and Thiel Bio. HistoSonics’ Edison system uses focused ultrasound histotripsy to destroy target tissue and is US Food and Drug Administration–cleared to treat liver tumors. The company plans to use the recent funding to expand to other indications such as kidney, pancreas, and prostate tumors.
EDAP TMS has entered into a €36 million multi-tranche credit facility with the European Investment Bank. Proceeds from the financing will be used to support the global expansion of the company’s Focal One robotic high-intensity focused ultrasound (HIFU) platform, the leading prostate focal therapy device in the US and Europe. The funds will also accelerate the development of new clinical indications for EDAP’s innovative HIFU technology.
Founded in 2024, Sonomind is a company based in Paris, France, that is developing a personalized transcranial neuromodulation system that enables noninvasive targeting of deep brain areas. The company recently raised €3 million ($3.53M), including €2 million ($2.35M) in seed capital from Critical Path Ventures. It has also secured support from the French Government as part of the France 2030 initiative, benefitting from €1 million ($1.18M) in non-dilutive funding awarded through Bpifrance Deeptech development aid. The funds will enable company to launch a clinical trial in patients with drug-resistant depression and finalize development of its noninvasive technology.
SecondWave Systems is developing a novel ultrasound-based treatment for inflammatory disorders and has closed a $7M Series A financing round. The financing was led by Treo Ventures and a major healthcare strategic, with participation from Scientific Health Development and the University of Minnesota’s Discovery Capital and SSBCI funds. The company will use the funding to support its next clinical study, which will build on data from their first-in-human study that demonstrated a significant reduction in rheumatoid arthritis disease activity.
Petal Surgical Emerges from Stealth with an Oversubscribed Series A
Petal Surgical is a new company that is developing a novel approach to surgery using acoustic liquefaction (a unique form of histotripsy), artificial intelligence, and robotics. The company has raised nearly $20M in total funding, including a $10M Series A that was co-led by K50 Ventures and TSVC, with participation from Draper’s, ShangBay Capital, Eliot Horowitz, Dr. Frederic H. Moll, and other notable venture capitalists and industry pioneers.